General discussion, page-17558

No, what you are to understand if you are able, is that their intentions for that pipeline are fully-funded.

Look, Incannex communicated to the market more than two years ago that their main drug candidates would require somewhere in the vicinity of 200 million dollars to bring to fruition. You need take only one look at their healthy but not unlimited balance, to know that they don't have enough funds to run all pending clinical trials concomitantly. But that's fine because they don't have to. Their strategy has always been to advance their drug candidates to the point where one or more trigger an acquisition offer. You know this.

This does not mean they have to put all of them through clinical trials in the next two years.

Are IHL-675a and IHL-42x not enough for you? Would you want them to be putting more candidates through clinical trials in parallel with 30M in the bank? I hope you don't think that would be a good idea.